Home › Stock screens › GLP-1 and obesity drug stocks
Best GLP-1 and obesity drug stocks
The incretin market is the largest new pharmaceutical category in decades, and supply capacity has been the binding constraint, not demand.
The screen: 4 US exchange-listed companies in Health Care, 3 of which pay a dividend. Size mix: 2 mega-cap, 1 large-cap, 1 small-cap.
What separates the winners from the losers here
- Manufacturing capacity commitments
- Reimbursement decisions by large payers
- Oral formulations as the next competitive step
The full list
| Ticker | Company | Price | 1D | What it is |
|---|---|---|---|---|
| LLY | Eli Lilly | $1152.05 | -0.07% | Incretin franchise driving obesity and diabetes growth. |
| AMGN | Amgen | $385.75 | +0.03% | Biologics portfolio with an obesity pipeline option. |
| NVO | Novo Nordisk (ADR) | $43.27 | +0.07% | The Danish maker of Ozempic and Wegovy, the other half of the GLP-1 duopoly with Eli Lilly. |
| VKTX | Viking Therapeutics | $28.97 | -0.05% | Clinical-stage biotech racing an oral and injectable dual GLP-1/GIP agonist through Phase 3 obesity trials. |
Where to buy them
To hold these as real shares you need a stockbroker rather than a CFD provider. If you only want exposure to the price movement, a share CFD does that with leverage — and without ownership.
Compare every broker for US stocks →
Frequently asked questions
How many GLP-1 and obesity drug stocks are in this list?
4, drawn from our US exchange-listed universe and spread across 1 sector. 3 of them pay a dividend.
Is this a list of GLP-1 and obesity drug stocks to buy?
No. It is a screen — a defined, reproducible filter over a stated universe. A screen tells you which companies share a characteristic; it says nothing about whether the price you would pay today is a sensible one. Nothing here is investment advice.
What is the main risk with GLP-1 and obesity drug stocks?
Extreme expectations are already priced in; a credible competitor or a reimbursement refusal is enough to reset the multiple.
How do I actually buy these from outside the US?
You need a broker that accepts your country of residence and gives you access to US exchanges. To own the shares outright, that usually means an international stockbroker plus a W-8BEN form to claim your treaty rate on dividend withholding.
Screen definition reviewed September 2026. Universe: US exchange-listed securities tracked by InvestingTrading. This page is information, not investment advice.